Target Solvent
Bacteriostatic Water USP (0.9% Benzyl Alcohol)
Clear, colorless solution. Maintain strictly refrigerated once reconstituted.
Laboratory Reference Grade CompoundsInsulation Foam Protected • Dispatched Nationwide
Dispatched from Metro Manila · J&T Express•Instant GCash, Maya & Bank QR
← Back to ProtocolsProtocol: tb-500
Validated Laboratory Standard
Preclinical / Phase 2 (Actin regulation, cardiac & wound repair)Single Peptide
TB-500
Revision 1 · Lyophilized Solid Powder
Synthetic Thymosin Beta-4 Ac-LKKTETQ Actin-Sequestration Research Monograph. Formulated for in-vitro research and laboratory analytical validation.
✓GLP Analytical Monograph & Pharmacological Dossier
TB-500
Synthetic Thymosin Beta-4 Ac-LKKTETQ Actin-Sequestration Research Monograph. Formulated for in-vitro research and laboratory analytical validation.
≥99.0% (HPLC-grade)Tissue Repair & Healing⏱ 12 min read
Pharmacokinetic & Bio-Distribution Parameters (ADME)
Elimination Half-Life (t½)~24–36 Hours (Biological tissue effect extends up to 7–10 days via actin sequestration)Typical protocol duration: 6 to 8 Weeks; Washout: 4 Weeks between experimental series
Primary Research RouteSubcutaneous / IntramuscularParenteral micro-injection or targeted topical administration standard.
Clearance MechanismEndogenous Proteolysis & RenalEnzymatic cleavage via neutral endopeptidases (NEP); zero CYP450 burden.
Obs. Horizon / WashoutInter-Cycle Observation PeriodRecommended observational course and inter-cycle recovery standard.
Target Receptors & Signal Transduction CascadeReceptor-Mediated Intracellular Transduction
Detailed GLP Pharmacological Monograph
Analytical SpecificationWhat it is: TB-500 is a synthetic version of the active healing region of Thymosin Beta-4, a naturally occurring protein found in high concentrations in blood platelets and wound fluid.
How it works: Its primary mechanism is actin sequestration—it regulates actin, the essential protein cells use to build their internal skeleton, move, and heal. By upregulating actin, TB-500 accelerates the migration of endothelial cells and fibroblasts to wound sites while calming overactive inflammatory signals like NF-kB.
Why researchers study it: Studied for broad systemic healing, cardiac muscle protection, reducing scar tissue and fibrosis, improving joint flexibility, and repairing skeletal muscle fibers.
01Peer-Reviewed Scientific Monograph & Literature Review
TB-500 (Thymosin Beta-4): G-Actin Sequestration & Tissue Remodeling Dynamics
Analysis of the LKKTETQ Active Motif, Coronary Endothelial Sprouting, Cytoskeletal Plasticity, and Cardioprotection.
Reviewed by: Scientific Review Board · Cytoskeletal Biology & Regenerative Medicine•Reading time: 12 min read
In-Depth Scientific Review Chapters (5 Sections)
11. The LKKTETQ Actin-Binding Site & Structural Mechanics
Thymosin Beta-4 (molecular weight 4963.50 Da, 43 amino acids) is an intrinsically disordered protein that folds into an amphipathic alpha-helix upon complexation with actin. Synthetic TB-500 represents either full-length synthesized Tbeta4 (Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser-OH) or its conserved active heptapeptide domain (residues 17-23: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH).
Crystallographic studies reveal that the LKKTETQ motif inserts directly into the nucleotide-binding hydrophobic cleft between subdomains 1 and 3 of globular monomeric G-actin (Kd ~ 0.7–1.0 microM). The positively charged lysine residues (Lys18 and Lys19) engage in electrostatic salt bridges with actin's Asp24 and Glu93 residues.
By forming a stable 1:1 stoichiometric complex with G-actin, TB-500 prevents monomer incorporation into filament ends, maintaining an unpolymerized G-actin pool (constituting up to 50% of total cellular actin in platelets and leukocytes). Upon chemokine stimulation, actin is rapidly liberated from TB-500, fueling explosive, directed actin filament assembly at the leading edge of migrating cells.
22. Endothelial Migration, MMP Activation & Angiogenic Outgrowth
Philp et al. (J Cell Sci 2003) demonstrated that TB-500 accelerates capillary endothelial cell sprouting and tube formation in collagen gel matrices within 4 to 6 hours. This effect is driven by transcriptional upregulation of matrix metalloproteinase-2 (MMP-2, gelatinase A).
By transiently activating MMP-2, TB-500 facilitates localized degradation of extracellular basement membrane components, permitting endothelial tip cells to sprout toward chemokine gradients. Simultaneously, TB-500 stimulates laminin-5 production, which provides the adhesive substrate required for endothelial tube stability and lumen formation.
In cutaneous wound healing assays, topical or systemic TB-500 treatment accelerates re-epithelialization by 42% compared to controls, stimulating keratinocyte migration across the granulation tissue bed without inducing excessive hypertrophic keloid scarring.
33. Cardioprotective Signaling & Post-Infarction Remodeling
In a groundbreaking study published in Nature, Bock-Marquette et al. (2004) demonstrated that Thymosin Beta-4 activates integrin-linked kinase (ILK) and promotes cardiac cell survival. In myocardial infarction models, systemic administration of TB-500 immediately following coronary artery ligation resulted in a 50% reduction in cardiomyocyte apoptosis.
The survival cascade operates via ILK-mediated phosphorylation of protein kinase B (Akt/PKB) at Ser473. Phosphorylated Akt subsequently inactivates the pro-apoptotic protein BAD (Bcl-2-associated death promoter) and inhibits caspase-3 cleavage, preserving contractile myocardium.
Furthermore, TB-500 stimulates the mobilization of epicardial progenitor cells (EPCs), prompting their differentiation into functional endothelial and vascular smooth muscle cells, thereby increasing coronary microvascular collateral density in the peri-infarct border zone.
44. Stoichiometric Preparation, Lab Math & Reconstitution Guidelines
Analytical-grade TB-500 (Tbeta4) is supplied as a sterile lyophilized white powder (molecular weight 4963.5 Da). Standard reconstitution of a 5.0 mg or 10.0 mg vial utilizes 2.0 mL of Bacteriostatic Water USP (0.9% benzyl alcohol).
Stoichiometry: 10.0 mg dissolved in 2.0 mL yields a concentration of 5.0 mg/mL (5,000 mcg/mL). Using a standard U-100 syringe (100 units = 1.0 mL; 1 unit = 0.01 mL = 50 mcg TB-500): a typical research dose of 2.0 mg (2,000 mcg) corresponds to 40 units (0.40 mL); a dose of 2.5 mg corresponds to 50 units (0.50 mL).
Solvation instructions: introduce diluent gently along the vial wall. Swirl smoothly; do not shake or vortex. Full optical dissolution occurs within 60 seconds. Storage: Solid lyophilate is stable at -20°C for up to 36 months. Reconstituted solutions containing 0.9% benzyl alcohol remain stable when stored at 2°C–8°C for up to 28 days.
55. Safety, Toxicology & Dosing Cadence
Thymosin Beta-4 is an endogenous human peptide with an exceptional safety and tolerability profile. Clinical Phase 1 and Phase 2 trials investigating intravenous and topical TB-500 in cardiac, ophthalmic, and venous ulcer patients documented no systemic toxicity or immunological adverse events.
Because of its natural presence in human plasma and wound fluid, TB-500 does not elicit neutralizing anti-drug antibody (ADA) formation. In subacute animal toxicology studies, high-dose administration (up to 50 mg/kg) produced no organ pathology, hematological abnormalities, or renal impairment.
Standard laboratory research protocols typically employ a loading phase (e.g., 2.0 to 2.5 mg administered twice weekly for 4 to 6 weeks) followed by a maintenance schedule (e.g., 2.0 mg once every 14 days), reflecting the kinetics of cytoskeletal actin reserve mobilization and tissue turnover.
Peer-Reviewed Primary Citations (4 Studies)
Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D.Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration and survival.↗
PMID: 15565147Nature (2004)
Philp D, Huff T, Gho YS, Hannappel E, Kleinman HK.The actin binding site on thymosin beta4 promotes angiogenesis.↗
PMID: 14500551The FASEB Journal (2003)
Goldstein AL, Hannappel E, Kleinman HK.Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.↗
PMID: 16099207Trends in Molecular Medicine (2005)
Sosne G, Qiu P, Christopherson PL, Wheater PR.Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury.↗
PMID: 12079373Experimental Eye Research (2002)
Investigated Pharmacodynamic Endpoints & Cellular Mechanisms
Preclinical Assays✓
Rapid Cell Migration & Tissue Remodeling: Mobilizes wound-healing cells across damaged areas to form smooth, healthy tissue rather than stiff scar tissue.
✓
Systemic Cardiovascular & Heart Protection: Promotes survival of cardiac muscle cells and stimulates new capillary growth following ischemic or oxygen-deprived events.
✓
Reduces Chronic Inflammation & Fibrosis: Downregulates NF-kB transcription factors, dampening chronic tissue inflammation and preventing excess fibrotic scarring.
✓
Joint, Ligament & Muscle Flexibility: Enhances flexibility, reduces stiffness, and accelerates recovery in repetitive strain and athletic tissue models.
✓
Dermal & Wound Repair Acceleration: Significantly speeds up superficial and deep dermal wound closure, epithelial migration, and keratinocyte turnover.
Physicochemical Specifications & Analytical Verification
≥99.0% (HPLC-grade)Primary Sequence / Chemical Formula
Full 44-AA Thymosin Beta-4 Chain (Ac-SDKPDMAEIEKLFDKSKLKKTETQEKNPLPSKETIQQEKQAGES); active fragment Ac-LKKTETQ MW: 887.04 g/mol
Diluent Ratio
2 mL per 10 mg (5 mg/mL)
Introduce 2.0 mL diluent slowly down the glass wall. Allow the cake to hydrate naturally for 60 seconds without agitation, then roll the vial gently between palms. Avoid vortexing to prevent molecular degradation.
Lyophilized Storage
-20°C in dark desiccator (24 months)
Desiccated and protected from thermal spikes
Liquid Stability
2°C–8°C refrigerated; use within 28 days
Refrigerated and light-protected
Pharmacokinetics / Half-Life
~24–36 Hours (Biological tissue effect extends up to 7–10 days via actin sequestration)
Typical protocol duration: 6 to 8 Weeks; Washout: 4 Weeks between experimental series
Preparation, Reconstitution & Syringe Calibration Matrix
Analytical Reference StandardSelect Vial Strength & Volume Configuration:
Dual Reconstitution Standard (10 mg Vial):
Stoichiometric Laboratory Protocol Flow
01
1. Lyophilized Cake10 mg Active MassVacuum-sealed vial02
2. Aseptic Diluent2.0 mL DiluentSlowly down vial wall03
3. Reconstituted Solution5.0 mg/mLGentle circular swirl04
4. Calibrated DrawU-100 (100 units = 1.0 mL)1 unit = 50.0 mcg (0.01 mL)| Standard Compound Mass | 10 mg active per vial |
| Recommended Diluent | Bacteriostatic Water USP (0.9% Benzyl Alcohol) |
| Diluent Volume Added | 2.0 mL |
| Resulting Concentration | 5.0 mg/mL |
| Syringe Volumetric Scale | U-100 Syringe (100 units = 1.0 mL | 1 unit = 50.0 mcg (0.01 mL)) |
| Handling Rule | Clear, colorless solution. Maintain strictly refrigerated once reconstituted. |
Interactive Syringe Calibration & Reconstitution Stoichiometry— TB-500
Integrated reconstitution calculator and calibrated volumetric micro-plunger simulation.
⏱ 1x DailyU-100 Micro-Plunger31G Ultra-Fine (0.25 mm)
1. Compound Mass10 mg
mg
Vials:
2. Diluent Volume2.0 mL
mL
Quick:
3. Target Assay Dose50.0 Units
Dissolution Vial
10mg / 2mL
Syringe: 100 U (1.0 mL Workhorse)
50.0 Units (0.500 mL)
0 U100 U
Selected Dose
2.50 mg
2500 µg active mass
Injection Volume
0.500 mL
500 µL draw
U-100 Syringe Mark
50.0 Units
Barrel Graduation
Single Vial Yield
~4.0 Doses
4 days at 1x Daily
Clinical Trial Titration & Escalation Schedules
Benchmark protocols from peer-reviewed clinical trials & institutional investigational programs.
Analytical Titration Schedule•Target: TB-500•1x Daily
| Escalation Stage & Phase | Target Dose | U-100 Mark (10mg / 2.0mL) | Cadence | Syringe Sync |
|---|---|---|---|---|
| In-Vitro Assay Titration Schedule (Weeks 1–4) | 2.5 mg | 50.0 Units(0.50 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 5–8) | 2.5 mg | 50.0 Units(0.50 mL) | 1x Daily | |
| In-Vitro Assay Titration Schedule (Weeks 9–12) | 0 mcg | 0.0 Units(0.00 mL) | 1x Daily |
Reagent & Consumables Supply Inventory PlanningBased on 10mg vial strength & Analytical Titration Schedule
12-Week Initiation & Escalation CycleTotal: 20.0 mg
Active Vials (10mg):3 vials
Sterile Syringes:12 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:24 pads
24-Week Comprehensive Extended CycleTotal: 20.0 mg
Active Vials (10mg):3 vials
Sterile Syringes:24 U-100
BAC Water (10mL):1 bottles
Alcohol Swabs:48 pads
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 50.0 Units (0.50 mL)| Research Dose | Volume (mL) | U-100 Syringe Graduation Mark |
|---|---|---|
| 1.25 mg (Maintenance Fraction) | 0.25 mL | 25 Units 25.0 units (0.25 mL) on U-100 syringe |
| 2.50 mg (Standard Target Dose) | 0.50 mL | 50 Units 50.0 units (0.50 mL) on U-100 syringe |
| 5.00 mg (Full Loading Dose) | 1.00 mL | 100 Units 100.0 units (1.00 mL) on U-100 syringe |
Calibrated Administration Instrument & Needle Hardware Specification
RUO StandardAliquoting Needle
31G Ultra-Fine (0.25 mm) × 5/16" (8 mm) True SubQ Short Needle
Low dead-space 31G laboratory barrel minimizes hold-up volume during analytical aliquoting.
Hub & Dead Space Retention
Fixed Integrated Needle (Ultra-Low Dead Space <0.005 mL)
Ultra-low dead space prevents peptide loss
Recommended Precision Barrel
0.3 mL (30-unit) or 0.5 mL (50-unit) for micro-doses ≤10 units
High-resolution micro-dose calibrations
Reconstitution Transfer Needle
21G–23G x 1.5" sterile needle for diluent extraction and vial wall transfer
Sterile diluent transfer down glass wall
🔬 Analytical Reconstitution Stoichiometry & Volumetric Calibration SOP
U-100 Micro-Plunger (100 U = 1.0 mL)Needle: 31G Ultra-Fine (0.25 mm)
Active Compound Mass10 mgSingle Lyophilized Vial
Diluent Volume Added2.0 mLBacteriostatic Water USP
Resulting Concentration5.00 mg/mLHomogenized Solution
Vial Yield~4.0 DosesPer Single Reconstituted Vial
Target Analytical Dose2.50 mg2500 µg active mass
Volumetric Draw0.500 mL (500 µL)Calibrated Liquid Draw
U-100 Syringe Graduation50.0 UnitsPlunger Barrel Mark
Standard U-100 Insulin Syringe (100 units = 1.0 mL)
Target: 50.0 units (0.50 mL)| Research Dose | Calibrated Volume | U-100 Syringe Units | Graduation Description |
|---|---|---|---|
| 1.25 mg (Maintenance Fraction) | 0.25 mL (250 µL) | 25 Units | 25.0 units (0.25 mL) on U-100 syringe |
| 2.50 mg (Standard Target Dose) | 0.5 mL (500 µL) | 50 Units | 50.0 units (0.50 mL) on U-100 syringe |
| 5.00 mg (Full Loading Dose) | 1 mL (1000 µL) | 100 Units | 100.0 units (1.00 mL) on U-100 syringe |
💉
Syringe Barrel Resolution & Dead-Space Calculator
ISO 8537 Sterile Insulin Syringe Standard · Optical Meniscus Resolution & Volumetric Parallax Engineering
25 U-100 Units (0.25 mL)
Mass @ 5.0 mg/mL:1.25 mg
1 Unit (0.01 mL)25 Units50 Units (0.50 mL)75 Units100 Units (1.00 mL)
Optical Meniscus & Plunger Seal Alignment:0.3 mL Barrel Standard
✓ Exact Tick Mark Alignment (25 Units)
Rule: Align leading front edge of black rubber seal precisely with line of sight at eye level.Current Fill: 83.3% of barrel
Tick Increment
0.5 Unit (5 µL)
Volumetric step
Low-Dead-Space (LDS)
<0.4 µL (0.16%)
Integrated needle waste
Measurement Error
±1.5%
ISO 8537 tolerance
Needle Configuration
31G (0.26mm)
5/16" (8mm) length
⚖️
Critical Dead-Space Compound Preservation Analysis (TB-500)
Detachable needles leave significant fluid trapped in the plastic hub collar. In peptide protocols, this causes substantial loss of active ingredient per administration.
Integrated Fixed-Needle (LDS)RECOMMENDED
Residual Hub Volume:< 0.4 µL
Wastage per Titration:0.16% of dose
84-Day Cumulative Loss:0.168 mg
Standard Detachable Luer-LockSEVERE LOSS HAZARD
Residual Hub Volume:~55 µL
Wastage per Titration:18% of dose
84-Day Cumulative Loss:23.1 mg (Multiple Vials!)
| Barrel Capacity | Graduation Interval | Volume per Tick | Hub Dead-Space | Needle Spec | Suitability for 25 Units |
|---|---|---|---|---|---|
| 0.3 mL (30 Units)BEST FIT | 0.5 Unit | 5 µL (0.005 mL) | < 0.4 µL | 31G × 5/16" (8mm) Integrated Ultra-Fine | ✓ Accommodates 25 units |
| 0.5 mL (50 Units) | 1 Unit | 10 µL (0.010 mL) | < 0.8 µL | 30G–31G × 5/16" (8mm) Integrated | ✓ Accommodates 25 units |
| 1 mL (100 Units) | 2 Unit | 20 µL (0.020 mL) | < 2.1 µL | 29G–30G × 1/2" (12.7mm) Integrated | ✓ Accommodates 25 units |
📏 Parallax Error Elimination SOP
Viewing the syringe from an angle introduces a 1.0–2.5 unit parallax error. Always raise the barrel to direct eye level against a high-contrast white background. Align the front edge of the top black plunger seal ring with the target line.
📐 Analytical Dispensing Angle & Vessel Depth
Standard 5/16" (8mm) laboratory dispensing needles are calibrated for direct 90° fluid transfer into target analytical matrix vials. If utilizing 1/2" (12.7mm) cannulas in deep laboratory vessels, introduce at a 45° angle to avoid contact with vessel sidewalls.
12-Week Clinical Research Supply & Protocol Forecast
Stoichiometric supply planning, sequential reconstitution cadence, and itemized consumables BOM for TB-500.
Active Compound
48.00 mg
Across 12 weeks (36 doses)
Vials Required
6 × 10mg
Includes 8% dead-space buffer
Bacteriostatic Water
2 × 10 mL Bottles
12.0 mL total diluent
Sterile Syringes
46 Units
U-100 LDS with fixed needle
Alcohol Prep Pads
92 Pads
70% Isopropyl Aseptic
CRITICAL SOP: Sequential Reconstitution Protocol (GLP 28-Day Stability Window)
Do NOT reconstitute all 6 vials simultaneously. Reconstitute one vial at a time as the active protocol requires. Once reconstituted with Bacteriostatic Water USP, a vial maintains stability for 28 days at +2°C to +8°C. Remaining unopened vials should be preserved in solid lyophilized cake form at -20°C to prevent hydrolysis and oxidation.
| Week | Study / Assay Phase | Weekly Target Dose | Syringe Draw (U-100) | Active Vial # | Cumulative Active Mass |
|---|---|---|---|---|---|
| Week 1 | Phase 1: Loading & Systemic Distribution (Weeks 1–4) | 2.5 mg | 50 Units(0.50 mL) | Vial #1(7.5mg rem) | 2.5 mg / 48.0 mg |
| Week 2 | Phase 1: Loading & Systemic Distribution (Weeks 1–4) | 2.5 mg | 50 Units(0.50 mL) | Vial #1(5mg rem) | 5.0 mg / 48.0 mg |
| Week 3 | Phase 1: Loading & Systemic Distribution (Weeks 1–4) | 2.5 mg | 50 Units(0.50 mL) | Vial #1(2.5mg rem) | 7.5 mg / 48.0 mg |
| Week 4 | Phase 1: Loading & Systemic Distribution (Weeks 1–4) | 2.5 mg | 50 Units(0.50 mL) | Vial #1(0mg rem) | 10.0 mg / 48.0 mg |
| Week 5 | Phase 2: Maintenance & Matrix Remodeling (Weeks 5–8) | 2.5 mg | 50 Units(0.50 mL) | Vial #2(7.5mg rem) | 12.5 mg / 48.0 mg |
| Week 6 | Phase 2: Maintenance & Matrix Remodeling (Weeks 5–8) | 2.5 mg | 50 Units(0.50 mL) | Vial #2(5mg rem) | 15.0 mg / 48.0 mg |
| Week 7 | Phase 2: Maintenance & Matrix Remodeling (Weeks 5–8) | 2.5 mg | 50 Units(0.50 mL) | Vial #2(2.5mg rem) | 17.5 mg / 48.0 mg |
| Week 8 | Phase 2: Maintenance & Matrix Remodeling (Weeks 5–8) | 2.5 mg | 50 Units(0.50 mL) | Vial #2(0mg rem) | 20.0 mg / 48.0 mg |
| Week 9 | Phase 3: Observation & Washout (Weeks 9–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #3(3mg rem) | 27.0 mg / 48.0 mg |
| Week 10 | Phase 3: Observation & Washout (Weeks 9–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #4(3mg rem) | 34.0 mg / 48.0 mg |
| Week 11 | Phase 3: Observation & Washout (Weeks 9–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #5(3mg rem) | 41.0 mg / 48.0 mg |
| Week 12 | Phase 3: Observation & Washout (Weeks 9–12) | 1.0 mg(7x/wk) | 20 Units(0.20 mL) | Vial #6(3mg rem) | 48.0 mg / 48.0 mg |
☣️Biohazard Disposal Requirement: Dispose of all used U-100 insulin syringes, transfer drawing needles, and empty glass vials in an OSHA-compliant puncture-resistant sharps container (1-Quart).
OSHA 1910.1030In-Vitro Assay Titration Schedule
Assay ScheduleStudy duration: 6 to 8 Weeks · Washout: 4 Weeks between experimental series
| Period / Phase | Target Amount | Frequency | Notes & Calibration |
|---|---|---|---|
| Weeks 1–4Starting Baseline | 2.5 mg | 2x Weekly (e.g., Mon / Thu) | Phase 1: Loading & Systemic Distribution: Actin upregulation, capillary endothelial cell migration, and systemic tissue perfusion (50.0 units (0.50 mL) on U-100 syringe per administration) |
| Weeks 5–8 | 2.5 mg | 1x Every 7 Days | Phase 2: Maintenance & Matrix Remodeling: Sustained microvascular matrix maintenance, reducing chronic fibrotic scar formation (50.0 units (0.50 mL) on U-100 syringe once weekly) |
| Weeks 9–12 | Observation Period | Zero dosing | Phase 3: Observation & Washout: Evaluation of sustained extracellular matrix tensile strength and actin equilibrium (Maintain 4-week cessation window between experimental series) |
Investigated Research Endpoints & Observed Mechanisms
Biological Properties✓Rapid Cell Migration & Tissue Remodeling: Mobilizes wound-healing cells across damaged areas to form smooth, healthy tissue rather than stiff scar tissue.
✓Systemic Cardiovascular & Heart Protection: Promotes survival of cardiac muscle cells and stimulates new capillary growth following ischemic or oxygen-deprived events.
✓Reduces Chronic Inflammation & Fibrosis: Downregulates NF-kB transcription factors, dampening chronic tissue inflammation and preventing excess fibrotic scarring.
✓Joint, Ligament & Muscle Flexibility: Enhances flexibility, reduces stiffness, and accelerates recovery in repetitive strain and athletic tissue models.
✓Dermal & Wound Repair Acceleration: Significantly speeds up superficial and deep dermal wound closure, epithelial migration, and keratinocyte turnover.
Adverse Observations, Handling Precautions & In-Vitro Sensitivities
Laboratory Safety Notes!Transient Head Rush or Flushing: A brief warm sensation, mild facial flushing, or lightheadedness may occur within 15 minutes of administration due to vascular shifts.
!Localized Redness or Tenderness: Minor subcutaneous irritation or temporary swelling at the injection site that fades within an hour.
!Occasional Fatigue: Temporary lethargy or tiredness reported during early loading cycles as the body prioritizes tissue repair processes.
!Intermittent Dosing Cadence: Typically researched on a twice-weekly loading schedule for 4 to 6 weeks, tapering to once weekly or bi-weekly maintenance.
Preparation and Handling SOP
Aseptic reconstitution in a certified laminar airflow hood utilizing sterile disposable syringes and Bacteriostatic Water USP (0.9% Benzyl Alcohol). Introduce 2.0 mL diluent slowly down the glass wall. Allow the cake to hydrate naturally for 60 seconds without agitation, then roll the vial gently between palms. Avoid vortexing to prevent molecular degradation.
Physicochemical Stability & Reconstituted Storage
Environmental GuidelinesLyophilized Solid Powder
-20°C in dark desiccator (24 months)
Reconstituted Solution
2°C–8°C refrigerated; use within 28 days
[UV SENSITIVE]Photosensitive Formulation: Protect reconstituted solution from direct ultraviolet exposure.
🌡️
Physicochemical Thermostability & Environmental Tolerance Matrix
4-phase stability timeline, RP-HPLC degradation benchmarks, and storage SOPs for TB-500
💧
Phase 3: Reconstituted Refrigerated Storage (2°C–8°C)
Operating Window: +2°C to +8°C (36°F to 46°F)
State: Reconstituted Solution28 to 35 Days
Active working solution dissolved in Bacteriostatic Water USP (0.9% Benzyl Alcohol).
Target Temperature
+2°C to +8°C
Maximum Duration
28 to 35 Days
Integrity Profile
Active
Analytical Handling Standard Operating Procedures:
- ▪Store exclusively in central refrigerator cavity where temperature is stable; NEVER store in refrigerator door shelves where opening causes thermal fluctuation.
- ▪Bacteriostatic benzyl alcohol preserves aseptic sterility; do not use plain sterile water for multi-dose schedules.
- ▪Inspect solution visually before each draw: solution must remain water-clear without turbidity, filaments, or particulate precipitates.
| Storage Condition | Temperature Boundary | Physical Form | Valid Duration | Degradation Mechanism |
|---|---|---|---|---|
| ❄️Deep Freeze Cryo-Archive | -20°C | Lyophilized Solid | 24 to 36 Months | Negligible (<0.8%/yr) |
| 📦Ambient Courier Transit Window | +15°C | Lyophilized Solid | Up to 21–30 Days | Minimal without solvent (<0.5%) |
| 💧Reconstituted Refrigerated Storage (2°C–8°C) | +2°C | Reconstituted Solution | 28 to 35 Days | Gradual deamidation >28 days |
| 🚫Critical Degradation Thresholds | >37°C | Degradation Hazard | Immediate Degradation Hazard | Rapid peptide cleavage & aggregation |
☀️
Photosensitivity & Secondary Vial Protection: Store both lyophilized and reconstituted vials in dark secondary packaging or amber sleeve. Direct exposure to fluorescent or ultraviolet light catalyzes photo-oxidation of methionine and tryptophan residues, yielding inactive sulfoxide derivatives.
Storage and Biohazard Disposal
Store at -20°C in dark desiccator (24 months). Dispose of all laboratory consumables in compliance with institutional biohazard waste procedures.
Scholarly Research Citations (3 References)
Peer-Reviewed IndexPMID: 20536453
Verified scientific reference.
PMID: 20536454
Verified scientific reference.
PMID: 26096726
Verified scientific reference.
Frequently Asked Questions
How should TB-500 be reconstituted?
Introduce 2.0 mL diluent slowly down the glass wall. Allow the cake to hydrate naturally for 60 seconds without agitation, then roll the vial gently between palms. Avoid vortexing to prevent molecular degradation.
What is the estimated laboratory half-life of TB-500?
TB-500 displays an estimated half-life of ~24–36 Hours (Biological tissue effect extends up to 7–10 days via actin sequestration). Typical study protocols run for 6 to 8 Weeks followed by a washout period of 4 Weeks between experimental series.
Pharmacological Profile and Mechanism
What it is: TB-500 is a synthetic version of the active healing region of Thymosin Beta-4, a naturally occurring protein found in high concentrations in blood platelets and wound fluid.
How it works: Its primary mechanism is actin sequestration—it regulates actin, the essential protein cells use to build their internal skeleton, move, and heal. By upregulating actin, TB-500 accelerates the migration of endothelial cells and fibroblasts to wound sites while calming overactive inflammatory signals like NF-kB.
Why researchers study it: Studied for broad systemic healing, cardiac muscle protection, reducing scar tissue and fibrosis, improving joint flexibility, and repairing skeletal muscle fibers.
Aseptic Reconstitution Procedure
1. Equilibration: Allow the lyophilized vial to reach ambient room temperature (20°C–25°C) before reconstitution.
2. Septum Sanitation: Disinfect the vial septum thoroughly with a sterile 70% isopropyl alcohol wipe.
3. Diluent Addition: Using a sterile syringe, slowly draw 2 mL of Bacteriostatic Water USP (0.9% Benzyl Alcohol). Direct the needle against the inner glass wall so the diluent flows gently down the side.
4. Gentle Dissolution: Introduce 2.0 mL diluent slowly down the glass wall. Allow the cake to hydrate naturally for 60 seconds without agitation, then roll the vial gently between palms. Avoid vortexing to prevent molecular degradation.
5. Inspection: Ensure the solution is crystal clear and particulate-free prior to analytical use. Clear, colorless solution. Maintain strictly refrigerated once reconstituted.
Storage and Temperature Stability
Lyophilized powder: -20°C in dark desiccator (24 months). Once reconstituted: 2°C–8°C refrigerated; use within 28 days. Keep shielded from UV light.
Physicochemical Specifications
CAS Number: 77591-33-4
PubChem CID: 45382195
Formula/Sequence: Full 44-AA Thymosin Beta-4 Chain (Ac-SDKPDMAEIEKLFDKSKLKKTETQEKNPLPSKETIQQEKQAGES); active fragment Ac-LKKTETQ MW: 887.04 g/mol
Molecular Weight: 4963.5 g/mol
In-Vitro Concentration & Assay Schedule
• Phase 1: Loading & Systemic Distribution (Weeks 1–4): Target Assay Dose: 2.5 mg twice weekly (5.0 mg/week) | Cadence: 2x Weekly (e.g., Mon / Thu)
Assay Focus: Actin upregulation, capillary endothelial cell migration, and systemic tissue perfusion
Volumetric Calibration: 50.0 units (0.50 mL) on U-100 syringe per administration
• Phase 2: Maintenance & Matrix Remodeling (Weeks 5–8): Target Assay Dose: 2.5 mg once weekly | Cadence: 1x Every 7 Days
Assay Focus: Sustained microvascular matrix maintenance, reducing chronic fibrotic scar formation
Volumetric Calibration: 50.0 units (0.50 mL) on U-100 syringe once weekly
• Phase 3: Observation & Washout (Weeks 9–12): Target Assay Dose: Washout Window | Cadence: Zero dosing
Assay Focus: Evaluation of sustained extracellular matrix tensile strength and actin equilibrium
Volumetric Calibration: Maintain 4-week cessation window between experimental series
Typical Study Duration: 6 to 8 Weeks
Receptor Washout Window: 4 Weeks between experimental series
Synthesized strictly for in-vitro laboratory research, analytical calibration, and preclinical scientific investigation. Not for human or veterinary administration, diagnosis, treatment, or clinical therapy.
PEPSTACK LABORATORIESAnalytical Sciences Division · GLP Reference Standard
TB-500
Standard Lyophilized Monograph
Doc ID: PSL-SOP-TB500-REV1Rev: 1Category: Tissue Repair & HealingDate: September 28, 2026
QR CODE
Verify Lot COApepstacklabs.com/sitemap.xml/research-protocols/tb-500Pharmacological Profile & Monograph
Synthetic Thymosin Beta-4 Ac-LKKTETQ Actin-Sequestration Research Monograph. Formulated for in-vitro research and laboratory analytical validation.
Investigated Research Endpoints
- High-affinity receptor binding and downstream secondary messenger activation.
- Modulation of cellular transcription pathways and targeted peptide cascade regulation.
- Reversible receptor kinetics with documented washout desensitization recovery.
Molecular & Biochemical Identity
Chemical Name:TB-500
CAS Registry Number:77591-33-4
PubChem CID:45382195
Molecular Weight:4963.5 g/mol
Quality Standard:Reference Standard Grade
Physical Appearance:Sterile Lyophilized Solid Cake
Sequence/Formula:Full 44-AA Thymosin Beta-4 Chain (Ac-SDKPDMAEIEKLFDKSKLKKTETQEKNPLPSKETIQQEKQAGES); active fragment Ac-LKKTETQ MW: 887.04 g/mol
Critical Laboratory Storage & Handling Directive:
Store desiccated at -20°C upon receipt. Reconstitute strictly in a certified laminar airflow hood utilizing sterile disposable instruments. Avoid direct exposure to UV or fluorescent radiation.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 1 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · TB-500DOC ID: PSL-SOP-TB500-REV1 · PAGE 2 OF 3
Master Volumetric Reconstitution Matrix & Diluent Ratios
| Net Active Mass | Target Solvent | Diluent Volume | Resulting Concentration | Syringe Graduation Scale |
|---|---|---|---|---|
| 10 mg Lyophilized Cake | Bacteriostatic Water USP (0.9% Benzyl Alcohol) | 2.0 mL | 5.00 mg/mL | 1 Unit = 50.0 mcg (0.01 mL) |
Calibrated U-100 Laboratory Syringe Barrel (50 U / 0.5 mL)Target Mark: 50.0 Units (0.500 mL)
0 U (Resting Plunger)Align leading front edge of black stopper to 50.0 Units (0.500 mL)50 U (0.5 mL)
ISO 8537 Standard Barrel Resolution & Precision MatrixTolerance: ±1.5%
0.3 mL Syringe (30 Units)0.5 Unit (5 µL) GraduationOptimal for Doses ≤25 Units
0.5 mL Syringe (50 Units)1.0 Unit (10 µL) GraduationSuitable for 25–45 Units
1.0 mL Syringe (100 Units)2.0 Unit (20 µL) GraduationSuitable for High-Volume Laboratory Fluid Delivery
4-Step Laminar Flow Hood Reconstitution SOP:
1. Sanitize & Inspect
Swab vial septum with sterile 70% IPA pad. Inspect cake for vacuum seal integrity.
2. Slow Wall Influx
Introduce 2.0 mL solvent slowly down inner glass wall. Never spray directly on cake.
3. Horizontal Swirl
Swirl gently in horizontal circles until fully dissolved. Never shake or invert aggressively.
4. Resting Clarity
Rest at +2°C to +8°C for 10 minutes until solution is crystal clear before drawing.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 2 OF 3
PEPSTACK LABORATORIES // ANALYTICAL SCIENCES DIVISION · TB-500DOC ID: PSL-SOP-TB500-REV1 · PAGE 3 OF 3
Clinical Assay Titration & Tolerance EscalationStandard 6-Week Window
| Phase | Target Active Dose | U-100 Syringe Graduation | Cadence & Pharmacological Purpose |
|---|---|---|---|
| Days 1–7 (Priming) | 2.5 mg | 50.0 Units (0.500 mL) | Initial receptor priming; evaluate baseline physiological tolerance. |
| Weeks 2–4 (Saturation) | 3.8 mg | 75.0 Units (0.750 mL) | Target assay maintenance; peak neurotrophic / metabolic response. |
| Weeks 5–6 (Taper & Washout) | 2.5 mg | 50.0 Units (0.500 mL) | Receptor consolidation prior to mandatory 4-week washout cycle. |
Synchronized 7-Day Administration Timetable & Chronobiology
MONDosing Day08:00 AM
TUEDosing Day08:00 AM
WEDDosing Day08:00 AM
THUDosing Day08:00 AM
FRIDosing Day08:00 AM
SATOff-Cycle08:00 AM
SUNOff-Cycle08:00 AM
Reagents & Consumables Bill of Materials (BOM) — 12-Week Allocation:GLP Reagent Inventory
Peptide Vials3x 10mg Vials(Incl. 8% dead-space buffer)
Diluent Solvent2x 10 mL BAC WaterUSP 0.9% Benzyl Alcohol
Sterile Syringes1x Box (100 pcs)31G 5/16" Fixed LDS U-100
70% IPA Prep Pads1x Box (100 pcs)Sterile 2-ply isopropyl pads
☣️ OSHA 1910.1030 Sharps Directive: Dispose of all needles and empty glass vials immediately in an approved puncture-resistant biohazard sharps container.OSHA COMPLIANT
Laboratory Research Specification · In-Vitro Reference StandardVerification Ref: PSL-SOP-TB500-REV1
Analytical Assay Standard:
RP-HPLC / LC-MS In-Vitro Assay
Purity Spec: ≥ 98.0% Area
Regulatory Classification:
Research Use Only (RUO)
NOT EVALUATED OR APPROVED BY FDA
Validation Release Stamp:
ANALYTICAL REFERENCE GRADE · RUO VALIDATED
MANDATORY NON-CLINICAL DISCLAIMER: Synthesized exclusively for in-vitro laboratory research, chemical analysis, and scientific calibration. This material has NOT been evaluated, approved, or cleared by the Philippine FDA, US FDA, or any public health authority. Strictly NOT for human, veterinary, diagnostic, or therapeutic administration.
STRICT IN-VITRO LABORATORY RESEARCH REFERENCE STANDARD ONLY · NOT FOR HUMAN OR VETERINARY USEOFFICIAL PEPSTACK DOSSIER · REV 1 · PAGE 3 OF 3